AbbVie, Teva Hit With 2 More Niaspan Pay-For-Delay Suits

Law360, New York (May 1, 2013, 1:36 PM EDT) -- AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were hit Tuesday with a pair of putative antitrust class actions challenging a pay-for-delay deal that allegedly harmed consumers by keeping a generic version of AbbVie’s cholesterol drug Niaspan off the market.

The city of Providence, R.I., and a painters union's benefits fund lodged separate putative class actions, both alleging that an agreement between AbbVie and Teva kept a less-expensive generic version of Niaspan off the market for several years and, in effect, harmed competition and consumers who have...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.